In what CEO Albert Bourla called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new ...
Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract ...
Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry.
More than a year after filing for bankruptcy and inking an opioid settlement with dozens of states, Endo has taken another ...
For the second time in four weeks, GSK has settled a personal injury lawsuit in California state court over the heartburn ...
Sandoz and its subsidiary Fougera Pharmaceuticals have reached a $265 million settlement with direct purchasers for a full ...
Biotechs face a core communication challenge. How, in an industry that can spawn hundreds of startups every year, can you ...
Pfizer, GSK, Novartis, Johnson & Johnson and Sanofi all went big and made some major changes to their corporate looks and ...
Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown its staying power in older adults who received a single ...
As Johnson & Johnson's U.S. exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | As Johnson & Johnson's ...
Despite a restricted FDA label, Sarepta has seen early commercial success with its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. This year, the company aims to dramatically grow the drug's ...
Argenx is laying the groundwork for the anticipated expansion of its flagship drug into a new indication, kicking off the unbranded “Shining Through CIDP” campaign ahead of a potential FDA approval in ...